A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance
Open Access
- 19 December 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1327069
Abstract
Biofilms are a common survival strategy employed by bacteria in healthcare settings, which enhances their resistance to antimicrobial and biocidal agents making infections difficult to treat. Mechanisms of biofilm-induced antimicrobial resistance involve reduced penetration of antimicrobial agents, increased expression of efflux pumps, altered microbial physiology, and genetic changes in the bacterial population. Factors contributing to the formation of biofilms include nutrient availability, temperature, pH, surface properties, and microbial interactions. Biofilm-associated infections can have serious consequences for patient outcomes, and standard antimicrobial therapies are often ineffective against biofilm-associated bacteria, making diagnosis and treatment challenging. Novel strategies, including antibiotics combination therapies (such as daptomycin and vancomycin, colistin and azithromycin), biofilm-targeted agents (such as small molecules (LP3134, LP3145, LP4010, LP1062) target c-di-GMP), and immunomodulatory therapies (such as the anti-PcrV IgY antibodies which target Type IIIsecretion system), are being developed to combat biofilm-induced antimicrobial resistance. A multifaceted approach to diagnosis, treatment, and prevention is necessary to address this emerging problem in healthcare settings.Keywords
This publication has 116 references indexed in Scilit:
- Persistent bacterial infections and persister cellsNature Reviews Microbiology, 2017
- Bacterial community collapse: a meta‐analysis of the sinonasal microbiota in chronic rhinosinusitisEnvironmental Microbiology, 2017
- Critical review on biofilm methodsCritical Reviews in Microbiology, 2016
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico EvidencePLOS ONE, 2015
- Inflammation in cystic fibrosis lung disease: Pathogenesis and therapyJournal of Cystic Fibrosis, 2015
- Molecular Mechanism of MBX2319 Inhibition of Escherichia coli AcrB Multidrug Efflux Pump and Comparison with Other InhibitorsAntimicrobial Agents and Chemotherapy, 2014
- A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection ModelsAntimicrobial Agents and Chemotherapy, 2014
- High-Throughput Screening Using the Differential Radial Capillary Action of Ligand Assay Identifies Ebselen As an Inhibitor of Diguanylate CyclasesACS Chemical Biology, 2013
- Structural basis for the inhibition of bacterial multidrug exportersNature, 2013
- Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination TherapyAntimicrobial Agents and Chemotherapy, 2001